

Pablo Mir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7973904/publications.pdf>

Version: 2024-02-01

177
papers

9,009
citations

57758

44
h-index

53230

85
g-index

188
all docs

188
docs citations

188
times ranked

12786
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.2	1,414
2	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	12.6	1,085
3	Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). <i>Movement Disorders</i> , 2007, 22, 2210-2215.	3.9	304
4	Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. <i>Movement Disorders</i> , 2010, 25, 560-569.	3.9	223
5	International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. <i>Neurology</i> , 2009, 73, 1584-1591.	1.1	213
6	Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. <i>Movement Disorders</i> , 2008, 23, 1130-1136.	3.9	212
7	Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease. <i>Neurology</i> , 2009, 73, 113-119.	1.1	178
8	Changes in intracortical circuits of the human motor cortex following theta burst stimulation of the lateral cerebellum. <i>Clinical Neurophysiology</i> , 2008, 119, 2559-2569.	1.5	172
9	Burden, perceived health status, and mood among caregivers of Parkinson's disease patients. <i>Movement Disorders</i> , 2008, 23, 1673-1680.	3.9	166
10	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1133-1144.	2.2	156
11	De Novo Coding Variants Are Strongly Associated with Tourette Disorder. <i>Neuron</i> , 2017, 94, 486-499.e9.	8.1	155
12	Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 839-845.	1.9	153
13	Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. <i>Movement Disorders</i> , 2006, 21, 2181-2186.	3.9	137
14	In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. <i>Brain</i> , 2018, 141, 165-176.	7.6	135
15	Effects of Two Weeks of Cerebellar Theta Burst Stimulation in Cervical Dystonia Patients. <i>Brain Stimulation</i> , 2014, 7, 564-572.	1.6	124
16	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.8	111
17	The natural history of Unverricht-Lundborg disease: A report of eight genetically proven cases. <i>Movement Disorders</i> , 2008, 23, 107-113.	3.9	107
18	Secondary and primary dystonia: pathophysiological differences. <i>Brain</i> , 2013, 136, 2038-2049.	7.6	104

#	ARTICLE	IF	CITATIONS
19	Tremor stability index: a new tool for differential diagnosis in tremor syndromes. <i>Brain</i> , 2017, 140, 1977-1986.	7.6	103
20	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	1.9	100
21	Support of the histaminergic hypothesis in Tourette Syndrome: association of the histamine decarboxylase gene in a large sample of families. <i>Journal of Medical Genetics</i> , 2013, 50, 760-764.	3.2	92
22	GBA Variants Influence Motor and Non-Motor Features of Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0167749.	2.5	91
23	Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 825-831.	1.9	88
24	N370S GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1409-1422.	3.9	86
25	The epsilon-sarcoglycan gene in myoclonic syndromes. <i>Neurology</i> , 2005, 64, 737-739.	1.1	80
26	Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 70-75.	3.9	79
27	Study of Cerebello-Thalamocortical Pathway by Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Brain Stimulation</i> , 2013, 6, 582-589.	1.6	75
28	Dopaminergic drugs restore facilitatory premotor-motor interactions in Parkinson disease. <i>Neurology</i> , 2005, 64, 1906-1912.	1.1	71
29	Clinical features and ¹²³ I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 122-129.	1.9	71
30	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 151-157.	2.2	71
31	Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 519-525.	3.9	68
32	COPPADIS-2015 (COhort of Patients with Parkinson's Disease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	1.8	66
33	Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 744-748.	1.9	65
34	Diagnostic agreement in patients with psychogenic movement disorders. <i>Movement Disorders</i> , 2012, 27, 548-552.	3.9	60
35	Clinical features and ¹²³ I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 556-564.	6.4	59
36	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. <i>Journal of Neurology</i> , 2015, 262, 2201-2213.	3.6	59

#	ARTICLE	IF	CITATIONS
37	The clinical impression of severity index for Parkinson's disease: International validation study. <i>Movement Disorders</i> , 2009, 24, 211-217.	3.9	56
38	Motivation and movement: the effect of monetary incentive on performance speed. <i>Experimental Brain Research</i> , 2011, 209, 551-559.	1.5	55
39	Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. <i>Journal of Neurology</i> , 2012, 259, 1668-1672.	3.6	54
40	Genome-wide association study in musician's dystonia: A risk variant at the arylsulfatase G locus?. <i>Movement Disorders</i> , 2014, 29, 921-927.	3.9	53
41	Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 561-569.	3.6	53
42	Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	1.1	53
43	Atypical movement disorders in antiphospholipid syndrome. <i>Movement Disorders</i> , 2006, 21, 944-949.	3.9	50
44	European Academy of Neurology/Movement Disorder Society's European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. <i>Movement Disorders</i> , 2022, 37, 1360-1374.	3.9	49
45	Abnormal cortical and spinal inhibition in paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2004, 128, 291-299.	7.6	47
46	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	3.9	47
47	Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson's disease using [123I]FP-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 112-119.	6.4	46
48	Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone. <i>Neurological Sciences</i> , 2003, 24, 318-321.	1.9	44
49	Clinical, genetic and neuropathological characterization of spinocerebellar ataxia type 37. <i>Brain</i> , 2018, 141, 1981-1997.	7.6	40
50	Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 1210-1223.	3.3	40
51	Neurophysiological changes after intramuscular injection of botulinum toxin. <i>Clinical Neurophysiology</i> , 2012, 123, 54-60.	1.5	39
52	Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1737-1740.	3.9	39
53	Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 41-45.	2.1	37
54	Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II. <i>Neurología</i> , 2013, 28, 558-583.	0.7	37

#	ARTICLE	IF	CITATIONS
55	Alteration of central motor excitability in a patient with hemimasticatory spasm after treatment with botulinum toxin injections. <i>Movement Disorders</i> , 2006, 21, 73-78.	3.9	36
56	Pre- and perinatal complications in relation to Tourette syndrome and co-occurring obsessive-compulsive disorder and attention-deficit/hyperactivity disorder. <i>Journal of Psychiatric Research</i> , 2016, 82, 126-135.	3.1	36
57	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 91-109.	4.7	36
58	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double-Blind Primary Endpoint. <i>Neuromodulation</i> , 2022, 25, 817-828.	0.8	34
59	Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene. <i>Movement Disorders</i> , 2005, 20, 243-245.	3.9	33
60	Low serum uric acid concentration in Parkinson's disease in southern Spain. <i>European Journal of Neurology</i> , 2013, 20, 208-210.	3.3	33
61	Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain. <i>European Journal of Neurology</i> , 2009, 16, 957-960.	3.3	32
62	Motivational modulation of bradykinesia in Parkinson's disease off and on dopaminergic medication. <i>Journal of Neurology</i> , 2014, 261, 1080-1089.	3.6	32
63	COPPADIS 2015 Cohort of Patients with Parkinson's Disease in Tj ETQq1 1 0.784314 rgBT 1000 subjects included. Results from the baseline evaluation. <i>European Journal of Neurology</i> , 2019, 26, 1399-1407.	3.3	32
64	Statuslike SUNCT in Two Young Women. <i>Headache</i> , 2001, 41, 826-829.	3.9	31
65	Association of Group A <i>Streptococcus</i> Exposure and Exacerbations of Chronic Tic Disorders. <i>Neurology</i> , 2021, 96, e1680-e1693.	1.1	30
66	Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 526-532.	3.9	29
67	Informe de la Fundación del Cerebro sobre el impacto social de la enfermedad de Parkinson en España. <i>Neurología</i> , 2016, 31, 401-413.	0.7	29
68	Motor system inhibition in dopa-responsive dystonia and its modulation by treatment. <i>Neurology</i> , 2006, 66, 1088-1090.	1.1	27
69	The effect of BDNF val66met polymorphism on visuomotor adaptation. <i>Experimental Brain Research</i> , 2012, 223, 43-50.	1.5	26
70	Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation. <i>Journal of Neurophysiology</i> , 2013, 109, 1315-1322.	1.8	26
71	Tics and Other Stereotyped Movements as Side Effects of Pharmacological Treatment. <i>International Review of Neurobiology</i> , 2013, 112, 481-494.	2.0	26
72	The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. <i>Neurological Sciences</i> , 2015, 36, 275-279.	1.9	25

#	ARTICLE	IF	CITATIONS
73	Long-term effectiveness of levodopa+carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2016, 6, 289-298.	2.2	25
74	Abnormal cerebellar connectivity and plasticity in isolated cervical dystonia. <i>PLoS ONE</i> , 2019, 14, e0211367.	2.5	25
75	Role of ANO3 mutations in dystonia: A large-scale mutational screening study. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 196-200.	2.2	25
76	Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0175560.	2.5	24
77	Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial. <i>Journal of Neural Transmission</i> , 2014, 121, 357-366.	2.8	23
78	Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 301-316.	3.2	23
79	Aberrant cortical associative plasticity associated with severe adult Tourette syndrome. <i>Movement Disorders</i> , 2015, 30, 431-435.	3.9	22
80	Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype. <i>PLoS ONE</i> , 2017, 12, e0174644.	2.5	22
81	European Academy of Neurology/Movement Disorder Society -European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. <i>European Journal of Neurology</i> , 2022, 29, 2580-2595.	3.3	22
82	Mitochondrial DNA A4336G Mutation in Alzheimer's and Parkinson's Diseases. <i>European Neurology</i> , 2002, 48, 34-36.	1.4	19
83	Abnormal sensorimotor plasticity in CADASIL correlates with neuropsychological impairment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 329-336.	1.9	19
84	Improvement of impulse control disorders associated with levodopa+carbidopa intestinal gel treatment in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1279-1287.	3.6	19
85	Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice: the CDEPA questionnaire. <i>Npj Parkinson's Disease</i> , 2018, 4, 20.	5.3	19
86	A Bayesian spatial model for neuroimaging data based on biologically informed basis functions. <i>NeuroImage</i> , 2017, 161, 134-148.	4.2	18
87	Increased bilirubin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 213-216.	2.2	18
88	Predictors of clinically significant quality of life impairment in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 118.	5.3	17
89	Intermediate alleles at the FRAXA and FRAXE loci in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 281-284.	2.2	16
90	The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain. <i>Neurología (English Edition)</i> , 2016, 31, 401-413.	0.4	16

#	ARTICLE	IF	CITATIONS
91	Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with aâ€ˆGBAâ€ˆ mutation. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S117.	1.1	16
92	InÂˆvivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 68-75.	2.2	16
93	Lack of Association of Group A Streptococcal Infections and Onset of Tics. <i>Neurology</i> , 2022, 98, .	1.1	16
94	Clinical features and neuropsychological profile in vascular parkinsonism. <i>Journal of the Neurological Sciences</i> , 2014, 345, 193-197.	0.6	15
95	Lack of validation of variants associated with cervical dystonia risk: A GWAS replication study. <i>Movement Disorders</i> , 2014, 29, 1825-1828.	3.9	15
96	The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016, 263, 730-734.	3.6	15
97	Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinsonâ€™s Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 642-658.	2.3	15
98	Antiâ€ˆdopamine D2 receptor antibodies in chronic tic disorders. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 1205-1212.	2.1	15
99	Serum lipid profile among sporadic and familial forms of Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 59.	5.3	15
100	Common variation in the <i>LRRK2</i> gene is a risk factor for Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1823-1826.	3.9	14
101	Parieto-motor Cortical Dysfunction in Primary Cervical Dystonia. <i>Brain Stimulation</i> , 2014, 7, 650-657.	1.6	14
102	A geroscience approach for Parkinsonâ€™s disease: Conceptual framework and design of PROPAG-AGEING project. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111426.	4.6	14
103	CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntingtonâ€™s disease. <i>Science Translational Medicine</i> , 2021, 13, eabe7104.	12.4	14
104	Parieto-motor functional connectivity is impaired in Parkinson's disease. <i>Brain Stimulation</i> , 2013, 6, 147-154.	1.6	13
105	The impact of freezing of gait on functional dependency in Parkinsonâ€™s disease with regard to motor phenotype. <i>Neurological Sciences</i> , 2020, 41, 2883-2892.	1.9	13
106	Impaired motor cortical plasticity associated with cannabis use disorder in young adults. <i>Addiction Biology</i> , 2021, 26, e12912.	2.6	13
107	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120148.	0.6	13
108	<i>GDNF</i> gene is associated with tourette syndrome in a family study. <i>Movement Disorders</i> , 2015, 30, 1115-1120.	3.9	11

#	ARTICLE	IF	CITATIONS
109	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019, 126, 1599-1608.	2.8	11
110	Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges. <i>Neuroscience Letters</i> , 2020, 719, 133679.	2.1	11
111	Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117109.	0.6	11
112	Paroxysmal dyskinesia with interictal myoclonus and dystonia: A report of two cases. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 250-252.	2.2	10
113	Restless legs may be associated with the post-polio syndrome. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 74-75.	2.2	10
114	Genetic association of sirtuin genes and Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2237-2241.	3.6	10
115	BDNF Val66Met polymorphism in primary adult-onset dystonia: A case-control study and meta-analysis. <i>Movement Disorders</i> , 2014, 29, 1083-1086.	3.9	10
116	Systematic mutational analysis of FBXO7 in a Parkinson's disease population from southern Spain. <i>Neurobiology of Aging</i> , 2014, 35, 727.e5-727.e7.	3.1	10
117	Low serum uric acid levels in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 402-405.	3.9	10
118	Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. <i>Journal of Parkinson's Disease</i> , 2019, 9, 173-182.	2.8	10
119	Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. <i>Parkinson's Disease</i> , 2021, 2021, 1-16.	1.1	10
120	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 626.	2.5	10
121	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. <i>Journal of Parkinson's Disease</i> , 2022, 12, 315-331.	2.8	10
122	Sensory perception changes induced by transcranial magnetic stimulation over the primary somatosensory cortex in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2058-2064.	3.9	9
123	Trait- and state-dependent cortical inhibitory deficits in bipolar disorder. <i>Bipolar Disorders</i> , 2016, 18, 261-271.	1.9	9
124	Depression is Associated with Impulse-compulsive Behaviors in Parkinson's disease. <i>Journal of Affective Disorders</i> , 2021, 280, 77-89.	4.1	9
125	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. <i>Diagnostics</i> , 2021, 11, 1801.	2.6	9
126	Increased Stroke Risk in Patients with Parkinson's Disease with <i>LRRK2</i> Mutations. <i>Movement Disorders</i> , 2022, 37, 225-227.	3.9	9

#	ARTICLE	IF	CITATIONS
127	Glucose-6-phosphate dehydrogenase activity in Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 1850-1851.	3.6	8
128	Functional neuroimaging in the diagnosis of patients with parkinsonism: Update and recommendations for clinical use. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 215-226.	0.2	8
129	Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 43.	2.0	8
130	Cluster headache with aura. <i>Journal of Headache and Pain</i> , 2002, 3, 105-110.	6.0	7
131	<i>DRD1</i> gene dystonic tremor presenting as a scan without evidence of dopaminergic deficit. <i>Movement Disorders</i> , 2012, 27, 1469-1469.	3.9	7
132	TMEM230 in Parkinson's disease in a southern Spanish population. <i>PLoS ONE</i> , 2018, 13, e0197271.	2.5	7
133	Mood in Parkinson's disease: From early to late stage disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 627-646.	2.7	7
134	<i>NR4A2</i> Mutations Can Cause Intellectual Disability and Language Impairment With Persistent Dystonia-Parkinsonism. <i>Neurology: Genetics</i> , 2021, 7, e543.	1.9	7
135	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. <i>BMC Neurology</i> , 2021, 21, 477.	1.8	7
136	Analysis of c.801-2A>G mutation in the DNAJC6 gene in Parkinson's disease in southern Spain. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 248-249.	2.2	6
137	Genetic analysis of CHCHD2 in a southern Spanish population. <i>Neurobiology of Aging</i> , 2017, 50, 169.e1-169.e2.	3.1	6
138	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. <i>Scientific Reports</i> , 2020, 10, 16893.	3.3	6
139	Integrating genetic and clinical data to predict impulse control disorders in Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 459-468.	3.3	6
140	Long runs of homozygosity are associated with Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 142.	4.8	6
141	Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. <i>Brain Sciences</i> , 2021, 11, 1027.	2.3	6
142	Screening study of TUBB4A in isolated dystonia. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 118-120.	2.2	5
143	Quantitative Intensity Harmonization of Dopamine Transporter SPECT Images Using Gamma Mixture Models. <i>Molecular Imaging and Biology</i> , 2019, 21, 339-347.	2.6	5
144	Falls Predict Acute Hospitalization in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, , 1-20.	2.8	5

#	ARTICLE	IF	CITATIONS
145	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study. <i>Diagnostics</i> , 2022, 12, 1147.	2.6	5
146	PSMC1 Gene in Parkinson's Disease. <i>European Neurology</i> , 2012, 68, 193-198.	1.4	4
147	Spanish expert consensus on the use of safinamide in Parkinson's disease. <i>Neurología (English)</i> 10.784314 rgBT / Overlock	0.4	4
148	Secondary generalized dystonia without basal ganglia damage. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 121-123.	2.2	3
149	Lack of sequence variations in THAP1 gene and THAP1-binding sites in TOR1A promoter of DYT1 patients. <i>Movement Disorders</i> , 2012, 27, 917-917.	3.9	3
150	Abnormal sensorimotor integration correlates with cognitive profile in vascular parkinsonism. <i>Journal of the Neurological Sciences</i> , 2017, 377, 161-166.	0.6	3
151	Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson. <i>Neurología</i> , 2018, 36, 666-666.	0.7	3
152	A replication study of GWAS-genetic risk variants associated with Parkinson's disease in a Spanish population. <i>Neuroscience Letters</i> , 2019, 712, 134425.	2.1	3
153	Heredoataxia cerebelosa recesiva ARCA1/SCAR8: primeras familias detectadas en España. <i>Neurología</i> , 2022, 37, 257-262.	0.7	3
154	The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset. <i>Neurobiology of Aging</i> , 2021, 97, 144.e1-144.e3.	3.1	3
155	Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Parkinson's Disease</i> , 2022, 12, 935-955.	2.8	3
156	MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice. <i>Diagnostics</i> , 2022, 12, 55.	2.6	3
157	On the long-term outcome of orthostatic tremor. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1290-1291.	2.2	2
158	Enhanced Motivational Modulation of Motor Behaviour with Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	1.1	2
159	Mutational spectrum of GNAL, THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review. <i>European Journal of Neurology</i> , 2021, 28, 1188-1197.	3.3	2
160	Investigation of gene-environment interactions in relation to tic severity. <i>Journal of Neural Transmission</i> , 2021, 128, 1757-1765.	2.8	2
161	Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients. <i>Npj Parkinson's Disease</i> , 2021, 7, 78.	5.3	2
162	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Diagnostics</i> , 2021, 11, 2380.	2.6	2

#	ARTICLE	IF	CITATIONS
163	Adult form of Niemann-Pick type C with the variant biochemical phenotype on treatment with Miglustat. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 916-917.	2.2	1
164	Novel <i>Lrrk2</i> S1761R mutation is not a common cause of Parkinson's disease in Spain. <i>Movement Disorders</i> , 2013, 28, 248-248.	3.9	1
165	Automatic and voluntary motor inhibition: Intact processes for tic suppression?. <i>Movement Disorders</i> , 2018, 33, 1667-1669.	3.9	1
166	Trastornos de tics e impulso premonitorio: validaci3n de la versi3n espaola de la «Escala para el Impulso Premonitorio al Tic» en ni±os y adolescentes. <i>Neurologa</i> , 2023, 38, 319-325.	0.7	1
167	Manejo de la enfermedad de Parkinson y otros trastornos del movimiento en mujeres en edad f©rtil: parte 2. <i>Neurologa</i> , 2021, 36, 159-168.	0.7	1
168	Genetic landscape of Segawa disease in Spain. Long-term treatment outcomes. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 67-78.	2.2	1
169	TMS intensity and focality correlation with coil orientation at three non-motor regions. <i>Physics in Medicine and Biology</i> , 2022, 67, 055002.	3.0	1
170	Tic disorders and premonitory urges: validation of the Spanish-language version of the Premonitory Urge for Tics Scale in children and adolescents. <i>Neurologa (English Edition)</i> , 2023, 38, 319-325.	0.4	1
171	Le point de vue du neurologue. Situations cliniques. <i>Medecine Nucleaire</i> , 2007, 31, 76.	0.2	0
172	1.022 Adult onset dystonic tremor as differential diagnosis for Parkinson's disease: Detailed clinical description of 20 patients emphasizing non-motor symptoms including olfactory function. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S33.	2.2	0
173	Uso de la infusi3n intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en Espa±a. Subanálisis por comunidades autónomas. <i>Neurologa</i> , 2021, 36, 101-111.	0.7	0
174	Continuous intestinal infusion of levodopa+carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community. <i>Neurologa (English Edition)</i> , 2021, 36, 101-111.	0.4	0
175	Teaching Video NeuroImages: Clues in Myoclonus Evaluation: When to Consider Sialidosis. <i>Neurology</i> , 2021, 97, 10.1212/WNL.0000000000012464.	1.1	0
176	Neurophysiology of Paroxysmal Dyskinesia. , 2021, , 109-117.		0
177	Reply to: «Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations» <i>Movement Disorders</i> , 2022, 37, 1119-1120.	3.9	0